Omthera Pharmaceuticals announced the initiation of its Phase 3 EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial evaluating Epanova for the treatment of patients with very high triglycerides. The EVOLVE trial is a 12-week, multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of three doses of Epanova in patients with fasting triglyceride levels ≥500mg/dL. The primary endpoint is the percentage change in triglyceride level from baseline to week 12. The secondary endpoint is the reduction of non-HDL cholesterol.

Epanova is an omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  

For more information call (908) 741-4399 or visit www.omthera.com.